Log in
Enquire now
Alpha-9 Theranostics

Alpha-9 Theranostics

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.

OverviewStructured DataIssuesContributors

Contents

alpha9tx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biotechnology
Biotechnology
Genetics
Genetics
Life science
Life science
Pharmaceutical industry
Pharmaceutical industry
Location
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Canada
Canada
B2X
B2B
B2B
CEO
‌
David Hirsch
Founder
‌
David Perrin
Number of Employees (Ranges)
11 – 50
Email Address
info@a9oncology.com
Phone Number
+17782312500
Investors
Andreessen Horowitz (a16z)
Andreessen Horowitz (a16z)
Delos Capital
Delos Capital
Biotechnology Value Fund
Biotechnology Value Fund
Frazier Healthcare Partners
Frazier Healthcare Partners
Digitalis Ventures
Digitalis Ventures
Aberdeen Asset Management
Aberdeen Asset Management
Total Funding Amount (USD)
127,750,000
Latest Funding Round Date
October 23, 2024
CFO
‌
Matthias Jaffe
Latest Funding Type
Series C
Series C

Other attributes

Latest Funding Round Amount (USD)
127,750,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Alpha-9 Theranostics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.